Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

3 Reasons Not to Buy Johnson & Johnson Stock Just Because Its COVID Vaccine Pause Was Lifted

Roughly 57% of investor votes cast backed healthcare company Johnson & Johnson's executive pay for 2020, a low level of support for a proposal most shareholders usually rubberstamp.

J&J execs get pay raises, but only after bruising shareholder 'Vote No' campaign

Procter & Gamble

Southern Company

The more defensive sectors of the economy are usually some of the best places to find stocks with growing dividends. Companies that can navigate difficult economic conditions generally have consistent growth over a long period of time.

3 Income Favorites Raising Dividends

Which Dividend King is a better undervalued dividend stock to buy? Procter & Gamble Vs. Johnson & Johnson.

Procter & Gamble Vs. Johnson & Johnson: The Battle Of Dividend Royalty - Dividend Stock Analysis

Johnson & Johnson (NYSE:JNJ) has been in the news for a number of reasons lately.

Johnson & Johnson: A Huge Vaccine Upside

Experts say the pause should boost public confidence in vaccines.

Majority Of Americans Unwilling To Get Johnson & Johnson Shot After CDC Pause, Poll Suggests

Johnson & Johnson (NYSE: JNJ) is reportedly bringing back its plans to sell its breast implant unit, Mentor. Bloomberg reported that the company is working with an adviser on a sales process.

Johnson & Johnson Looks To Offload Breast Implant Business, Once Again: Bloomberg

Albertsons Companies

Lennox International

NXP Semiconductors

Tesla

Some of the stocks that may grab investor focus today are: Wall Street expects Lennox International Inc. (NYSE: LII) to report quarterly earnings at $1.29 per share on revenue of $788.00 million before the opening bell. Lennox shares fell 0.2% to close at $334.46 on Friday.

5 Stocks To Watch For April 26, 2021

“In the long run … people will realize that we take safety very seriously,” Fauci said.

Fauci Denies Johnson & Johnson Pause Will Contribute To Vaccine Hesitancy

Dr. Anthony Fauci on Sunday said he didn't believe that the pause of the Johson & Johnson COVID-19 vaccine, which lasted for about a week, would lead to further vaccine hesitancy among Americans because it showed the US' commitment to safety.  The US last week resumed the use of the J&J vaccine following a pause to allow regulators to examine the rare risk of blood clots associated with the shot. In resuming the rollout Friday, the FDA added a warning about the rare risk of clots in women under the age of 50.

Fauci doesn't believe the J&J vaccine pause will increase hesitancy over the shot: It shows 'we take safety very seriously'

Johnson & Johnson (NYSE: JNJ) got a reprieve after the Food and Drug Administration and the Centers for Disease Control revoked their earlier recommendation to pause the use of its COVID-19 vaccine. What Happened: The pause regarding the use of J&J's COVID-19 vaccine should be lifted and the use of it should resume, the FDA said in a statement.

Johnson & Johnson COVID-19 Cleared For Use Following Investigation Into Blood Clotting

Lawsuits delayed by the pandemic could give shareholders a nasty surprise in the months ahead.

This Risk Might Shock Anyone Holding Johnson & Johnson Stock

NEW BRUNSWICK, N.J., April 23, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company's COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).

Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision

U.S. lifts pause, allowing J&J COVID-19 vaccinations to resume

Johnson & Johnson shots were temporarily halted on April 13, following reports that several women developed blood clots in their brains.

CDC, FDA lift recommended pause on use of Johnson & Johnson Covid vaccine

The US will resume using Johnson & Johnson's COVID-19 vaccine, more than a week after regulators paused the rollout to investigate reports of rare but serious side effects. US health regulators are planning to add a warning to the vaccine about the risk of unusual blood clots in women under 50. Still, the shots remain a valuable tool to stop the pandemic, and US health authorities said the benefits of the vaccines in preventing COVID-19 outweigh the risks.

Johnson & Johnson's vaccine is resuming its US rollout after a pause to investigate blood clots

A panel of experts on Friday recommended the U.S. resume vaccinations with Johnson & Johnson's Covid shot, saying the benefits outweigh the risks. But JNJ stock was little moved after hours.

J&J Covid Vaccines Could Resume This Weekend Following CDC Panel Vote

A Centers for Disease Control and Prevention advisory committee recommended Friday that Covid-19 inoculations with the Johnson & Johnson vaccine begin again. The Advisory Committee on Immunization Practices found the benefits outweighed the risks as a small group of recipients developed blood clots. There are now 15 such cases confirmed. All the cases have been...

Los Angeles Prepared To Resume Johnson & Johnson Vaccine Use “Very Quickly” After CDC Panel OKs It

The pause on the J&J shots might be lifted soon.

CDC panel recommends resuming Johnson & Johnson vaccine

A Centers for Disease Control and Prevention committee voted to let Americans once again receive Johnson & Johnson's single-shot COVID-19 vaccine without any additional stipulations.

CDC panel recommends use of J&J's COVID vaccine, says benefits outweigh risks

A US medical panel has recommended resuming the use of the Johnson & Johnson COVID-19 vaccine.

US panel recommends resuming Johnson & Johnson COVID-19 vaccine

A CDC advisory panel on Friday recommended the U.S. resume using the Johnson and Johnson Covid-19 vaccine.

CDC panel recommends U.S. resume use of J&J Covid vaccine, saying benefits outweigh risks

Public health experts are recommending that the US resume using Johnson & Johnson's coronavirus vaccine, after immunizations were halted to investigate reports of rare blood clots. A Centers for Disease Control and Prevention advisory committee voted 10 to 4, with 1 abstention, on Friday that use of the shot should resume. US health regulators will now craft new language to be included along with the vaccine, warning of the risk of unusual clots in women under 50.

CDC panel says Johnson & Johnson's COVID-19 shot can be used again

JNJ is expecting revenue growth to come back strongly in FY21 after a pandemic-hit FY20 affected its consumer health and medical device divisions. The company is forecasting for a ~10-11% growth in reported sales and ~17%-19% increase in adjusted EPS of $9.42 - $9.57. As usual, management hiked the dividend by 5%.

Johnson & Johnson: Management Raises Guidance, Looks To Ignite Growth

"I think there's a huge amount of evidence that the benefit greatly outweighs this risk" when it comes to the J&J Covid vaccine, Dr. Wilbur Chen told CNBC.

News for Johnson & Johnson Stock (JNJ)